Defining the factors that contribute to on-target specificity of antisense oligonucleotides.
about
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersTargeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency.Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms.Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages.Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.Managing the sequence-specificity of antisense oligonucleotides in drug discovery.The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.Molecular Mechanisms of Antisense Oligonucleotides.A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides.Advances in therapeutic bacterial antisense biotechnology.Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs.Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
P2860
Q28821280-C43C8306-F308-4AAF-B02C-EB1A2E956573Q34344380-0364E5CB-1DE9-4252-B109-81AE7D845BF9Q35315759-43C0F9B7-E131-4D79-BDD2-4BBD4356DA07Q38291228-5D3060BF-8CAC-4A49-82CA-58F917A885ADQ38300866-0BFBA2CA-35B9-41FB-85D5-CCF6C489E662Q38807425-7B601C05-44FD-407F-A597-98275C0BE69DQ38828951-CBAD81FE-CF37-4280-87F1-3FF212A8D6DCQ40525237-484C550B-F27E-4BAF-A4F9-78962362CD2EQ42293314-8D3CCE2F-7603-4E78-AC65-C908EC90A772Q43101279-D02E51F1-97B3-45B2-B40E-12D08F43824FQ47325247-2457AB43-3E53-406E-BAE3-FBFB3BF978C9Q47374105-EF6C6716-2AD5-44AC-9749-0E7A23F0D055Q49489377-7BA09CFC-55B9-47E8-BC51-24E322A7FDCEQ52764171-BCF702BA-7CE8-420E-ABFD-7627198E8CE0Q55260229-429CB72F-B6CD-4333-8C4E-16541D93BECAQ58708488-60084CE9-3411-4667-A576-821AA1F722FC
P2860
Defining the factors that contribute to on-target specificity of antisense oligonucleotides.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Defining the factors that cont ...... of antisense oligonucleotides.
@ast
Defining the factors that cont ...... of antisense oligonucleotides.
@en
type
label
Defining the factors that cont ...... of antisense oligonucleotides.
@ast
Defining the factors that cont ...... of antisense oligonucleotides.
@en
prefLabel
Defining the factors that cont ...... of antisense oligonucleotides.
@ast
Defining the factors that cont ...... of antisense oligonucleotides.
@en
P2093
P2860
P1433
P1476
Defining the factors that cont ...... of antisense oligonucleotides.
@en
P2093
Josh Nichols
Stanley T Crooke
Timothy A Vickers
Walt F Lima
P2860
P304
P356
10.1371/JOURNAL.PONE.0101752
P407
P577
2014-07-29T00:00:00Z